What monitoring is recommended for a patient receiving denosumab therapy?

• A. Monitor calcium, phosphate, and renal function.
• B. Monitor thyroid hormones only.
• C. Monitor cholesterol.
• D. Monitor vitamin C.

Answer: (A)

Monitoring for denosumab centers on minerals and kidney function because this medicine suppresses bone breakdown, which can lower calcium levels in the blood. When bone resorption decreases, less calcium is released into the bloodstream, so hypocalcemia is a real risk—especially in patients who have vitamin D deficiency, malabsorption, or chronic kidney disease. That makes checking calcium essential to catch and treat low calcium early.

Phosphate is checked too because calcium and phosphate balance are interconnected in bone metabolism. Changes in bone turnover can lead to shifts in phosphate levels, so monitoring it helps detect broader mineral disturbance.

Renal function is important to monitor even though denosumab itself isn’t cleared by the kidneys. Kidney disease alters calcium and phosphate handling and can heighten the risk of hypocalcemia, plus it informs dosing considerations and the need for supplementation with calcium or vitamin D.

Thyroid hormones, cholesterol, and vitamin C aren’t directly tied to the safety monitoring needed for denosumab therapy, so they aren’t the primary parameters to track in this context.